Pharmaceuticals

Alumis

Alumis released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 1.741 M (forecast USD 2.493 M), actual EPS USD -0.7441 (forecast USD -0.77)

Alumis Announces Positive Phase 3 Clinical Trial Results for Envudeucitinib and Plans to Submit NDA in H2 2026

Alumis released FY2025 Q4 earnings on March 19 (EST), actual revenue USD 1.929 M (forecast USD 2.4 M), actual EPS USD -0.8875 (forecast USD -0.977)

Alumis released FY2025 Annual Earnings on March 19 (EST), actual revenue USD 24.05 M (forecast USD 24.28 M), actual EPS USD -2.8616 (forecast USD -2.961)

Alumis reports 2025 fiscal year results and confirms success of envudeucitinib phase 3 clinical trial

Insiders make a multi-million dollar investment in Alumis Inc.

Foresite Capital Management VI LLC and related entities acquire Alumis Inc. common stock

James B. Tananbaum Acquires Shares in Alumis Inc

Alumis Inc. Reports Q4 Earnings Miss

Alumis Reports Preliminary Financials and Plans Stock Issuance

Alumis Inc. Announces Upsized Underwritten Public Offering

Alumis' experimental drug meets main goal in late-stage studies

Alumis Inc. to Hold Conference Call to Report Preliminary Data from Phase 3 ONWARD Clinical Trial

Wells Fargo Analyst Reiterates Buy Rating on Alumis Inc.

Alumis Inc. Director Srinivas Akkaraju Acquires Common Stock

Los Angeles Capital Management Acquires Alumis Inc. Stock

H.C. Wainwright Analyst Reiterates Buy Rating on Alumis Inc.

Alumis released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 22.12 M, actual EPS USD -2.1169

Alumis released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 2.066 M (forecast USD 3.143 M), actual EPS USD -1.0638 (forecast USD -0.9162)

Alumis management to attend upcoming healthcare conferences in September

OPTIMI HEALTH CORP

Silexion Therapeutics

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

GCL Global

Arcadia Biosciences

Jupiter Neurosciences

ALMS

DXCM

SPRY

Healthcare stocks declined on Friday, with the NYSE Healthcare Index down 0.9%. Aardvark Therapeutics shares plummeted 31% after a clinical hold by the FDA. DexCom's shares rose over 6% following new long-term financial goals. ARS Pharmaceuticals and Alumis saw declines of nearly 5% and over 5%, respectively, due to wider losses and significant revenue drops.

Fidelity

DexCom

ARS Pharmaceuticals

Aardvark Therapeutics

iShares Global Healthcare

SPDR S&P Biotech

iShares Biotechnology ETF

iShares US Medical Devices

Health Care Select Sector SPDR

VanEck Biotech ETF

iShares US Pharma

SPDR S&P Health Equip

VG Health

Morgan Stanley

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Sector Update: Healthcare Stocks Softer Friday Afternoon

TNGX

Top analysts have downgraded several stocks, including Tango Therapeutics (from Overweight to Neutral), Viking Holdings (from Overweight to Equal-Weight), Alumis Inc (from Buy to Neutral), Aardvark Therapeutics (from Equal-Weight to Underweight), and A O Smith Corp (from Neutral to Underweight). Price targets were adjusted for each company. For detailed analyst ratings, visit the analyst ratings page.

benzinga_article

Tango Therapeutics

Viking

A.O Smith

This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

LABU

ARKG

SBIO

Alumis (ALMS) reported a Q1 net loss of $93.1 million, an improvement from a $99 million loss a year prior. Revenue fell to $1.7 million from $17.4 million, below the expected $2.1 million. The company holds $569.5 million in cash and expects to fund operations through Q4 2027. Shares dropped 2% in premarket trading.

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Factset Research

Alumis Q1 Loss Narrows, Revenue Falls; Shares Down Pre-Bell

Earnings Watch

Alumis | 8-K: FY2026 Q1 Revenue Misses Estimate at USD 1.741 M

Alumis | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 1.741 M

ACT Capital Management has acquired 174,250 shares of Alumis (NASDAQ:ALMS) for approximately $4.36 million, representing 3.02% of its reportable assets. The shares have surged 350% over the past year, driven by positive Phase 3 data for its drug targeting plaque psoriasis. Alumis, a clinical-stage biotechnology firm, focuses on autoimmune and neuroinflammatory disorders. Despite a $243 million net loss last year, the company has a strong cash position and upcoming drug catalysts, making it a potential investment opportunity, though risks remain.

nasdaq

Krystal Biotech

Chevron

Exxon Mobil

Celcuity

TG Therap

S&P 500

Netflix

NVIDIA

NVIDIA Corporation

Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug

Alumis (NASDAQ:ALMS) is set to release its Q1 2026 earnings on May 13, with analysts predicting a loss of $0.79 per share and revenue of $2.493 million. The company previously reported a loss of $0.95 per share for Q4 2025, missing estimates. Alumis shares opened at $26.13, with a market cap of $3.32 billion. Analysts have raised price targets for the stock, with an average target of $38.60. Institutional investors have also increased their holdings in the company recently.

Market Beat

UBS Group AG

Oppenheimer

BNP Paribas

Manulife Financial

MANULIFE-S

Alumis (ALMS) to Release Quarterly Earnings on Wednesday

Wells Fargo analyst Derek Archila has reaffirmed a Buy rating for Alumis Inc. (ALMS) with a price target of $49.00. The analyst has an average return of 20.9% and a 53.85% success rate on his stock recommendations. The overall analyst consensus for Alumis Inc. is a Strong Buy, with an average price target of $39.71.

Alumis(ALMS.US)